Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment and prevention of seizures in preeclampsia/eclampsia,Management of acute hypomagnesemia,Treatment of life-threatening ventricular arrhythmias (e.g., torsade de pointes),Off-label: acute asthma exacerbation, tetanus, and constipation
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Magnesium sulfate is primarily excreted unchanged by the kidneys. It does not undergo significant hepatic metabolism.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Approximately 30–40% bound to albumin.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.2–0.3 L/kg. Distributes mainly in extracellular fluid; crosses placenta and blood-brain barrier.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
IV: 100%. IM: ~80% (variable). Oral: <20% (poor, due to limited absorption; primarily used for catharsis).
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
GFR <20 m L/min: maximum dose 2 g; avoid use if anuria. GFR 20-50 m L/min: reduce dose by 25-50%.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
Child-Pugh Class B or C: reduce dose by 50% and monitor serum magnesium levels.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
IV: 20-40 mg/kg/dose (max 2 g) as 10% solution; for severe hypomagnesemia: 25-50 mg/kg/dose q4-6h.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Reduce initial dose by 25-50%; infuse over longer period; monitor renal function and serum magnesium closely.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Continuous infusion of magnesium sulfate can cause hypermagnesemia, which may lead to respiratory depression or cardiac arrest. Only use with continuous monitoring of serum magnesium levels and clinical status.
None
Risk of hypermagnesemia, especially in renal impairment; monitor serum magnesium levels, deep tendon reflexes, and respiratory rate; use with caution in patients with myasthenia gravis or heart block; avoid extravasation due to risk of tissue necrosis.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to magnesium sulfate; heart block or myocardial damage; severe renal impairment (anuria or oliguria); hypermagnesemia.
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No specific food interactions. However, high dietary magnesium intake from supplements or foods may increase risk of toxicity when receiving magnesium sulfate. Maintain adequate hydration.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Prolonged use (≥5-7 days) in pregnancy is associated with fetal hypocalcemia, skeletal demineralization, and neonatal hypermagnesemia. No increased risk of major malformations with standard short-term use. Third trimester: risk of neonatal hypotonia, respiratory depression if given near delivery. Continuous infusion for tocolysis >48 hours increases risk of neonatal bone abnormalities.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Magnesium is excreted into breast milk; estimated infant dose approximately 1-2% of maternal weight-adjusted dose. M/P ratio not established. Risk of infant diarrhea and hypotonia with high maternal doses. Avoid prolonged high-dose therapy during breastfeeding.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Increased renal clearance in pregnancy may necessitate higher doses to maintain therapeutic magnesium levels. Monitor serum magnesium levels closely and adjust infusion rate accordingly (usual loading dose 4-6 g IV, maintenance 1-2 g/h). In preeclampsia/eclampsia, target serum magnesium 4-7 m Eq/L.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Magnesium sulfate is first-line for eclampsia and severe preeclampsia. Monitor for loss of deep tendon reflexes (DTRs) as early sign of toxicity; DTRs disappear at ~10 m Eq/L serum magnesium. Calcium gluconate is the antidote for magnesium toxicity. Use with caution in renal impairment; dose adjustment recommended. IV administration can cause hypotension and bradycardia. Not compatible with solutions containing calcium; may precipitate.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Report any muscle weakness, difficulty breathing, or extreme drowsiness immediately.,You may experience warmth, flushing, or sweating during IV infusion.,Avoid driving or operating heavy machinery until effects are known.,Inform your doctor if you have kidney disease, heart block, or are taking other medications.,Use during pregnancy is typically under close monitoring; discuss risks and benefits.,Do not suddenly stop taking magnesium sulfate; follow prescribed tapering schedule.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Felbamate, an antiepileptic drug, potentiates the central nervous system (CNS) depressant effects of magnesium sulfate, a tocolytic and anticonvulsant agent. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, and impaired motor coordination. Clinically, concurrent use may exacerbate hypotonia, hyporeflexia, and somnolence, particularly in patients with renal impairment or those receiving high doses."
"Coadministration of Clevidipine, a dihydropyridine calcium channel blocker, and Magnesium sulfate, which acts as a physiological calcium antagonist, potentiates the hypotensive and negative inotropic effects due to additive inhibition of calcium influx into cardiac and vascular smooth muscle cells. This can lead to exaggerated reductions in blood pressure, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Severe hypotension and heart block have been reported, especially during intravenous administration of both agents."
"The combination of nicardipine, a calcium channel blocker, and magnesium sulfate, a calcium antagonist, synergistically reduces vascular smooth muscle contractility and myocardial conduction. This additive pharmacodynamic effect can lead to profound hypotension, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Clinically, patients may experience symptomatic hypotension, dizziness, or syncope, and in severe cases, cardiovascular collapse may occur."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAGNESIUM SULFATE IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
MAGNESIUM SULFATE IN PLASTIC CONTAINER is a Electrolyte that works by Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAGNESIUM SULFATE IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAGNESIUM SULFATE IN PLASTIC CONTAINER is: IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAGNESIUM SULFATE IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAGNESIUM SULFATE IN PLASTIC CONTAINER is classified as Category C. Prolonged use (≥5-7 days) in pregnancy is associated with fetal hypocalcemia, skeletal demineralization, and neonatal hypermagnesemia. No increased risk of major malformations with. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.